Quantcast

Latest Cancer immunotherapy Stories

2014-03-17 08:29:07

HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers. "Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective...

2014-03-13 08:28:19

SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company. Under the terms of the agreement, AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody...

2014-03-06 13:13:25

Ludwig researchers show that infecting just 1 tumor with a virus could boost the systemic effectiveness of cancer immunotherapy A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors. Published today in the journal Science Translational...

2014-02-27 12:27:11

WORCESTER, Mass. and TORONTO, Feb. 27, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of studies examining potential biomarkers associated with overall survival in prostate cancer patients treated with its immunotherapeutic agent AE37. The retrospective study examined data from 29 patients immunized as part of a Phase I study. The immunotherapeutic agent AE37 is being developed by Antigen Express, Inc....

2014-02-20 08:32:02

Data Support Ongoing Randomized Phase 2 Study in Recurrent or Metastatic Head and Neck Cancer SEATTLE, Feb. 20, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. announced today the presentation of clinical data of VTX-2337, a cancer immunotherapy, in combination with cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) at the 2014 Multidisciplinary Head and Neck Cancer Symposia in Scottsdale, Arizona. Results indicate that the...

2014-02-11 08:33:33

AMSTERDAM, February 11, 2014 /PRNewswire/ -- - SynCo's live microbial track record, GMP scale-up and commercial manufacturing capabilities will facilitate the advancement of Advaxis' ADXS-HPV program - SynCo Bio Partners B.V. [http://www.syncobiopartners.com ], a leading services provider for GMP manufacturing of live microbial vaccines and biotherapeutics today announces that they have entered into a long term manufacturing collaboration with Advaxis, Inc....

2014-02-11 04:22:13

NORTH BRUNSWICK, N.J., Feb. 11, 2014 /PRNewswire/ -- PDS Biotechnology Corp., a clinical-stage biotechnology company focused on the development of novel immunotherapy treatments for cancer and other chronic diseases, as well as novel preventive vaccines, today announced that the first patient has been successfully vaccinated with PDS0101 in a Phase 1 clinical trial in patients with cervical intraepithelial neoplasia. The trial which is being conducted at three leading gynecological...

2014-02-10 12:26:14

GOSSELIES, Belgium, February 10, 2014 /PRNewswire/ -- iTeos Therapeutics SA today announced the filing of the Company's first patent applications protecting proprietary inhibitors of the intracellular enzyme TDO2, which is expressed at high levels in specific cancers. iTeos Therapeutics has collaborated with Ludwig Cancer Research over the last year to identify small molecule inhibitors of the enzyme that display nanomolar potency, good selectivity, favorable pharmacokinetics...

2014-01-23 04:21:21

Inovio develops DNA-based immune booster (IL-33) that enhances T-cell responses and generates effective CD8 mediated tumor regression BLUE BELL, Pa., Jan. 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the...

2014-01-17 08:23:09

LOS ANGELES, Jan. 17, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for cancer, today announced the appointment of Rizwana F. Sproule, Ph.D., to the newly created position of Vice President, Regulatory Affairs. Dr. Sproule has over 16 years of experience in regulatory affairs for both biologics and small molecule therapeutics across multiple therapeutic areas. Her...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.